Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 2/2009

01-06-2009 | Original Research Article

Health-Related Quality of Life and Quality of Life in Type 2 Diabetes

Relationships in a Cross-Sectional Study

Authors: Dr Murali Sundaram, Jan Kavookjian, Julie Hicks Patrick

Published in: The Patient - Patient-Centered Outcomes Research | Issue 2/2009

Login to get access

Abstract

Background and objectives: Health-related quality of life (HR-QOL) and quality of life (QOL) are increasingly being examined as outcomes in assessments among patients with type 2 diabetes mellitus. However, there is a lack of standardization in interpreting the two outcomes and insufficient appreciation of the differences between HR-QOL and QOL. This study reports relationships between two instruments of HR-QOL and an instrument of QOL in a cross-sectional study of patients with type 2 diabetes.
Methods: Patients with type 2 diabetes at the outpatient clinics of a university hospital completed measures of generic health status (12-item Short-Form Health Survey [SF-12], version 2 and EQ-5D) and diabetes-specific QOL (Audit of Diabetes Dependent Quality of Life [ADDQoL]). Patient-reported data were merged with retrospective clinical data including glycosylated hemoglobin (HbA1c), co-morbidities, diabetes complications score, body mass index (BMI), and others, obtained from electronic medical records. A path model of our hypothesized relationships between the physical and psychological components of HR-QOL, overall HR-QOL, and QOL was tested in addition to examining bivariate correlations between these constructs. The fit of the path model was assessed using multiple indexes of fit, including an overall chi-squared (χ2) test, the Comparative Fit Index (CFI), the Tucker-Lewis Index (TLI), and the Root Mean Square Error Approximation (RMSEA). The differences in the association between clinical, medical history and sociodemographic variables with HR-QOL and QOL were explored employing univariate t-tests and ANOVAs as well as multiple regression models.
Results: The usable response rate was 44.3% (n = 385). The mean HbA1c of respondents was 7.2% (±1.4), mean duration of diabetes was 10.2 (±9.1) years, and 62.1% were obese (BMI ≥30kg/m2). About 49% of respondents were taking oral medications only, 31.7% were taking oral medications and insulin, and 9.4% were taking insulin only. Spearman correlations of the EQ-5Dindex were 0.640 with the SF Physical Component Score (PCS)-12, 0.534 with the SF Mental Component Score (MCS)-12, and 0.316 with the ADDQoL (all p<0.001). A path analytic model relating SF-12 scores with EQ-5Dindex and ADDQoL scores exhibited good fit (χ2 = 1.32; p = 0.250; CFI = 0.99; TLI = 0.99; RMSEA = 0.03). Insulin use and diabetes-related complications were significantly associated with poorer scores on all measures. Only ADDQoL scores were significantly better among those with the American Diabetes Association-recommended HbA1c level of <7.0% (p = 0.002). Obesity was significantly associated with impaired SF-12 and EQ-5Dindex scores but not ADDQoL scores, while depressive symptoms were significantly associated with poorer scores on all these measures. The included explanatory variables explained a greater proportion of the variance in HR-QOL (PCS-12, MCS-12, EQ-5Dindex) than in QOL (ADDQoL) scores.
Conclusion: The study found that HR-QOL measures showed small correlations with the impact of diabetes on QOL. The fit statistics supported the hypothesized relationships in the path model, and provided empirical evidence that HR-QOL is a subset of QOL. In comparison to HR-QOL, QOL was less explained by the included explanatory variables, suggesting a greater influence on QOL by factors not accounted for in the present study.
Literature
1.
go back to reference Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13(1): 36–41 Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13(1): 36–41
2.
go back to reference Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007; 10Suppl. 2: S66–75PubMedCrossRef Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007; 10Suppl. 2: S66–75PubMedCrossRef
3.
go back to reference Health and Quality of Life Outcomes. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79 [online]. Available from URL http://www.hqlo.com/content/4/1/79 [Accessed 2006 Dec 5] Health and Quality of Life Outcomes. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79 [online]. Available from URL http://​www.​hqlo.​com/​content/​4/​1/​79 [Accessed 2006 Dec 5]
4.
go back to reference Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17(4): 267–74PubMedCrossRef Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17(4): 267–74PubMedCrossRef
5.
go back to reference Anderson RM, Fitzgerald JT, Wisdom K, et al. A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 1997; 20(3): 299–305PubMedCrossRef Anderson RM, Fitzgerald JT, Wisdom K, et al. A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 1997; 20(3): 299–305PubMedCrossRef
6.
go back to reference Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008; 299(21): 2543–9PubMedCrossRef Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008; 299(21): 2543–9PubMedCrossRef
7.
go back to reference Rubin RR. Diabetes and quality of life. Diabetes Spectrum 2000; 13(1): 21–3 Rubin RR. Diabetes and quality of life. Diabetes Spectrum 2000; 13(1): 21–3
8.
go back to reference Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28(11): 2668–72PubMedCrossRef Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28(11): 2668–72PubMedCrossRef
9.
go back to reference Kleefstra N, Landman GW, Houweling ST, et al. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4). Diabetes Care 2008; 31(5): 932–3PubMedCrossRef Kleefstra N, Landman GW, Houweling ST, et al. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4). Diabetes Care 2008; 31(5): 932–3PubMedCrossRef
10.
go back to reference The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86CrossRef The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86CrossRef
11.
go back to reference United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53CrossRef United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53CrossRef
12.
go back to reference The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996; 19(3): 195–203CrossRef The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996; 19(3): 195–203CrossRef
13.
go back to reference United Kingdom Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22(7): 1125–36CrossRef United Kingdom Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22(7): 1125–36CrossRef
14.
go back to reference Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357(9249): 7–8PubMedCrossRef Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357(9249): 7–8PubMedCrossRef
15.
go back to reference Speight J. Assessing the impact of diabetes screening on quality of life or quality of health? Semantics are important. Diabetes Care 2002; 25(10): 1893–4PubMedCrossRef Speight J. Assessing the impact of diabetes screening on quality of life or quality of health? Semantics are important. Diabetes Care 2002; 25(10): 1893–4PubMedCrossRef
17.
go back to reference Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 191–201 Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 191–201
18.
go back to reference Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8(1-2): 79–91PubMedCrossRef Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8(1-2): 79–91PubMedCrossRef
19.
go back to reference Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002; 19(1): 1–11PubMedCrossRef Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002; 19(1): 1–11PubMedCrossRef
21.
22.
go back to reference Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3): 203–20PubMedCrossRef Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3): 203–20PubMedCrossRef
23.
go back to reference Ware Jr J, Kosinski M, Keller SD, et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3): 220–33PubMedCrossRef Ware Jr J, Kosinski M, Keller SD, et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3): 220–33PubMedCrossRef
24.
go back to reference Ware Jr J, Kosinski M, Turner-Bowker DM, et al. How to score Version 2 of the SF-12® Health Survey (with a supplement documenting Version 1). Lincoln (RI): Quality-Metric Inc., 2002 Ware Jr J, Kosinski M, Turner-Bowker DM, et al. How to score Version 2 of the SF-12® Health Survey (with a supplement documenting Version 1). Lincoln (RI): Quality-Metric Inc., 2002
25.
26.
go back to reference Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30(5 Suppl.): MS112–24PubMedCrossRef Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30(5 Suppl.): MS112–24PubMedCrossRef
27.
go back to reference Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20(4): 562–7PubMedCrossRef Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20(4): 562–7PubMedCrossRef
28.
go back to reference de Sonnaville JJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998; 21(6): 919–24PubMedCrossRef de Sonnaville JJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998; 21(6): 919–24PubMedCrossRef
29.
go back to reference Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in type 2 diabetes patients. Qual Life Res 2007; 16(2): 165–77PubMedCrossRef Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in type 2 diabetes patients. Qual Life Res 2007; 16(2): 165–77PubMedCrossRef
30.
go back to reference Ford ES, Moriarty DG, Zack MM, et al. Self-reported body mass index and health-related quality of life: findings from the Behavioral Risk Factor Surveillance System. Obes Res 2001; 9(1): 21–31PubMedCrossRef Ford ES, Moriarty DG, Zack MM, et al. Self-reported body mass index and health-related quality of life: findings from the Behavioral Risk Factor Surveillance System. Obes Res 2001; 9(1): 21–31PubMedCrossRef
31.
go back to reference Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003; 27(10): 1227–32PubMedCrossRef Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003; 27(10): 1227–32PubMedCrossRef
32.
go back to reference Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23(10): 1556–62PubMedCrossRef Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23(10): 1556–62PubMedCrossRef
33.
go back to reference Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160(21): 3278–85PubMedCrossRef Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160(21): 3278–85PubMedCrossRef
34.
go back to reference Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef
35.
go back to reference Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106(3): 203–14PubMed Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106(3): 203–14PubMed
36.
go back to reference American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28Suppl. 1: S4–36CrossRef American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28Suppl. 1: S4–36CrossRef
38.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef
39.
go back to reference D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12): 1429–33PubMedCrossRef D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12): 1429–33PubMedCrossRef
40.
go back to reference Arbuckle JL. Amos (version 4.0) [computer program]. Chicago (IL): Smallwaters Corporation, 1999 Arbuckle JL. Amos (version 4.0) [computer program]. Chicago (IL): Smallwaters Corporation, 1999
41.
go back to reference Byrne BM. Structural equation modeling with AMOS. Mahwah (NJ): Erlbaum, 2001 Byrne BM. Structural equation modeling with AMOS. Mahwah (NJ): Erlbaum, 2001
42.
go back to reference SPSS for Windows Release 14 [computer program]. Chicago (IL): SPSS Inc., 2004 SPSS for Windows Release 14 [computer program]. Chicago (IL): SPSS Inc., 2004
43.
go back to reference Sullivan M. The new subjective medicine: taking the patient’s point of view on health care and health. Soc Sci Med 2003; 56(7): 1595–604PubMedCrossRef Sullivan M. The new subjective medicine: taking the patient’s point of view on health care and health. Soc Sci Med 2003; 56(7): 1595–604PubMedCrossRef
44.
go back to reference Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36 Health Survey (version 2). 2nd ed. Lincoln (RI): QualityMetric Inc., 2006 Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36 Health Survey (version 2). 2nd ed. Lincoln (RI): QualityMetric Inc., 2006
45.
go back to reference Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): QualityMetric Inc., 2007 Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): QualityMetric Inc., 2007
46.
go back to reference Muntaner C, Barnett E. Depressive symptoms in rural West Virginia: labor market and health services correlates. J Health Care Poor Underserved 2000; 11(3): 284–300PubMedCrossRef Muntaner C, Barnett E. Depressive symptoms in rural West Virginia: labor market and health services correlates. J Health Care Poor Underserved 2000; 11(3): 284–300PubMedCrossRef
47.
go back to reference Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42(1): 17–27PubMedCrossRef Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42(1): 17–27PubMedCrossRef
48.
go back to reference Davis TM, Clifford RM, Davis WA. Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001; 52(1): 63–71PubMedCrossRef Davis TM, Clifford RM, Davis WA. Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001; 52(1): 63–71PubMedCrossRef
49.
go back to reference Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5(1): 57–66PubMedCrossRef Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5(1): 57–66PubMedCrossRef
50.
go back to reference Zhang X, Norris SL, Chowdhury FM, et al. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45(9): 820–34PubMedCrossRef Zhang X, Norris SL, Chowdhury FM, et al. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45(9): 820–34PubMedCrossRef
51.
go back to reference Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30(4): 795–800PubMedCrossRef Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30(4): 795–800PubMedCrossRef
Metadata
Title
Health-Related Quality of Life and Quality of Life in Type 2 Diabetes
Relationships in a Cross-Sectional Study
Authors
Dr Murali Sundaram
Jan Kavookjian
Julie Hicks Patrick
Publication date
01-06-2009
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 2/2009
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.2165/01312067-200902020-00008

Other articles of this Issue 2/2009

The Patient - Patient-Centered Outcomes Research 2/2009 Go to the issue

Original Research Article

Paying for Enhanced Service

Pioneer Profile

Jordan Louviere, PhD

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.